Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/185670
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEnrich Bengoa, Jennifer-
dc.contributor.authorManich Raventós, Gemma-
dc.contributor.authorValente, Tony-
dc.contributor.authorSanchez Molina, Paula-
dc.contributor.authorAlmolda, Beatriz-
dc.contributor.authorSolà i Subirana, Carme-
dc.contributor.authorSaura Martí, Josep-
dc.contributor.authorGonzález, Berta-
dc.contributor.authorCastellano, Bernardo-
dc.contributor.authorPerálvarez Marín, Alex-
dc.date.accessioned2022-05-17T17:00:30Z-
dc.date.available2022-05-17T17:00:30Z-
dc.date.issued2022-03-25-
dc.identifier.issn1661-6596-
dc.identifier.urihttp://hdl.handle.net/2445/185670-
dc.description.abstractTransient potential receptor vanilloid 2 (TRPV2) is widely expressed through the nervous system and specifically found in neuronal subpopulations and some glial cells. TRPV2 is known to be sensitized by methionine oxidation, which results from inflammation. Here we aim to characterize the expression and regulation of TRPV2 in myelination pathologies, such as hypomyelination and demyelination. We validated the interaction between TRPV2 and its putative interactor Opalin, an oligodendrocyte marker, in mixed glial cultures under pro- and anti-inflammatory conditions. Then, we characterized TRPV2 time-course expression in experimental animal models of hypomyelination (jimpy mice) and de-/remyelination (cuprizone intoxication and experimental autoimmune encephalomyelitis (EAE)). TRPV2 showed upregulation associated with remyelination, inflammation in cuprizone and EAE models, and downregulation in hypomyelinated jimpy mice. TRPV2 expression was altered in human samples of multiple sclerosis (MS) patients. Additionally, we analyzed the expression of methionine sulfoxide reductase A (MSRA), an enzyme that reduces oxidated methionines in TRPV2, which we found increased in inflammatory conditions. These results suggest that TRPV2 may be a key player in myelination in accordance with the recapitulation hypothesis, and that it may become an interesting clinical target in the treatment of demyelination disorders.-
dc.format.extent24 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijms23073617-
dc.relation.ispartofInternational Journal of Molecular Sciences, 2022, vol. 23, num. 7, p. 3617-
dc.relation.urihttps://doi.org/10.3390/ijms23073617-
dc.rightscc-by (c) Enrich Bengoa, Jennifer et al., 2022-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.sourceArticles publicats en revistes (Biomedicina)-
dc.subject.classificationMalalties del sistema nerviós central-
dc.subject.classificationMielina-
dc.subject.classificationEstrès oxidatiu-
dc.subject.classificationEsclerosi múltiple-
dc.subject.classificationCanals iònics-
dc.subject.otherCentral nervous system diseases-
dc.subject.otherMyelin sheath-
dc.subject.otherOxidative stress-
dc.subject.otherMultiple sclerosis-
dc.subject.otherIon channels-
dc.titleTRPV2: A Key Player in Myelination Disorders of the Central Nervous System-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec723053-
dc.date.updated2022-05-17T17:00:30Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid35408977-
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Biomedicina)

Files in This Item:
File Description SizeFormat 
723053.pdf4.13 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons